article thumbnail

Cell therapy fails to slow early type 1 diabetes, but safety is established

STAT

Tolerance is the holy grail in calming autoimmune disease, a truce in the immune system’s faulty battle against the body’s own fabric. In type 1 diabetes, immune fighters attack beta cells in the pancreas that produce insulin, the hormone that controls glucose levels in the blood.

Diabetes 331
article thumbnail

STAT+: In small study, weight loss drug boosts immune cells that help fight cancer

STAT

Prior research has shown that people with obesity have deficiencies in their “natural killer” cells, or NK cells — immune cells that help in combating cancer.

Immunity 255
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Pharmalittle: New medication appears to stave off type 1 diabetes; CRISPR pioneer founds another startup

STAT

Here’s the latest, and do keep in touch … A new medication appears to be helping stave off the development of type 1 diabetes , Nature writes. Approved last November in the United States, it’s also the first drug proven to delay the onset of an autoimmune disorder.

Diabetes 235
article thumbnail

STAT+: Brigham creates institute focused on immunology with record $100 million gift

STAT

The institute will be led by Brigham immunologist and principal investigator Vijay Kuchroo, who will lead teams dedicated to studying chronic inflammation and discovering drugs for conditions associated with it, such as food allergies and type 1 diabetes. Continue to STAT+ to read the full story…

Immunity 246
article thumbnail

STAT+: Flagship Pioneering launches Quotient, a new biotech, in two countries

STAT

Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes. Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age.

Diabetes 284
article thumbnail

Sanofi to acquire Provention Bio, adding to portfolio TZIELD for type diabetes (T1D)

LifeProNow

-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately $2.9

Diabetes 130
article thumbnail

Tackling diabetes & ALS with cell therapy

pharmaphorum

Israeli company Kadimastem is developing regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells to treat diseases such as Amyotrophic lateral sclerosis (ALS) and diabetes. Catherine Longworth spoke with Kadimastem’s head of diabetes research, Kfir Molakandov to find out more.

Diabetes 126